Bernhard Wittmann, managing director of Sigmapharm and MoNo, discusses the company’s product portfolio and the diverse tailored services for their partners. Furthermore, he provides an in-depth look into MoNo’s new 20 million EUR (24 million USD) CMO production plant that will be completed in 2019. The ten-fold increase in capacity will expand the company’s capabilities as well as open up new opportunities for future endeavours and expansion.
As managing director, could you please introduce Sigmapharm and MoNo to our international readers?
"Our business model is very effective as we not only sell our own products, but are equally partners, allowing us to gain a stronger foothold in the market."
